These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33251600)

  • 61. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis.
    McCollum AD; Paik A; Eichenfield LF
    Pediatr Dermatol; 2010; 27(5):425-36. PubMed ID: 20678096
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.
    Yin ZQ; Zhang WM; Song GX; Luo D
    J Dermatol; 2012 Jun; 39(6):520-6. PubMed ID: 22409418
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Experts' Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach.
    Zhao Z; Gao XH; Li W; Wang H; Liang Y; Tang J; Yao X; Zhao H; Luger T
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):933-947. PubMed ID: 35313362
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis.
    Huang X; Xu B
    Dermatology; 2015; 231(1):41-9. PubMed ID: 26043855
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Abramovits W; Hung P; Tong KB
    Am J Clin Dermatol; 2006; 7(4):213-22. PubMed ID: 16901181
    [TBL] [Abstract][Full Text] [Related]  

  • 66. What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
    Hanna S; Zip C; Shear NH
    J Cutan Med Surg; 2019; 23(4_suppl):19S-26S. PubMed ID: 31476938
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
    Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
    Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Study of the Atopic March: Development of Atopic Comorbidities.
    Schneider L; Hanifin J; Boguniewicz M; Eichenfield LF; Spergel JM; Dakovic R; Paller AS
    Pediatr Dermatol; 2016 Jul; 33(4):388-98. PubMed ID: 27273433
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Atopic dermatitis: a review of topical treatment options.
    Simpson EL
    Curr Med Res Opin; 2010 Mar; 26(3):633-40. PubMed ID: 20070141
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis.
    Luger T; Adaskevich U; Anfilova M; Dou X; Murashkin NN; Namazova-Baranova L; Nitochko O; Reda A; Svyatenko TV; Tamay Z; Tawara M; Vishneva EA; Vozianova S; Wang H; Zhao Z
    J Dermatol; 2021 Aug; 48(8):1139-1148. PubMed ID: 33963603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
    Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
    J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
    Czarnecka-Operacz M; Jenerowicz D
    J Dtsch Dermatol Ges; 2012 Mar; 10(3):167-72. PubMed ID: 21974750
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P; Ellis CN; Girolomoni G
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
    Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
    J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].
    Meurer M; Wozel G
    Hautarzt; 2003 May; 54(5):424-31. PubMed ID: 12719862
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
    Jensen JM; Scherer A; Wanke C; Bräutigam M; Bongiovanni S; Letzkus M; Staedtler F; Kehren J; Zuehlsdorf M; Schwarz T; Weichenthal M; Fölster-Holst R; Proksch E
    Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
    Thaçi D; Salgo R
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun; 16(2):58, 60-62. PubMed ID: 17992459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.
    Nghiem P; Pearson G; Langley RG
    J Am Acad Dermatol; 2002 Feb; 46(2):228-41. PubMed ID: 11807435
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
    Kapoor R; Hoffstad O; Bilker W; Margolis DJ
    Pediatr Dermatol; 2009; 26(6):682-7. PubMed ID: 20199441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.